Global Asthma Disease Market Expected to Reach USD 28.3 Billion by 2022 – Analysis by Asthma Type, Trigger, Drug Class and Therapy

Asthma Disease Market

Huge data and information of this Asthma Disease report has been collected from a multiple trustworthy sources such as journals, websites, white papers, annual reports of the companies, and mergers. This Asthma Disease market report works on all the aspects of market that are required to create the finest and top-notch market research report. The report makes use of an excellent research methodology which focuses on market share analysis and key trend analysis. It estimates CAGR values in percentages which designate the rise or fall occurring in the market for particular product for the specific forecast period. The insights provided in this Asthma Disease market research report are based upon SWOT analysis on which businesses can rely confidently.

Global asthma disease market is rise gradually to an estimated value of USD 31.37 Billion by 2026 registering a steady CAGR of 4.3% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing, concerns regarding the health of patients, increasing pollution, consumption of tobacco and smoke.

For In-Depth Review | Get Free Sample Copy@

Market Definition: Global Asthma Disease Market

Asthma disease is chronic inflammation disease characterized by narrowing the airways and production of excessive mucus which results in periodic or repeated attack of breathlessness and wheezing. The patient with asthma disease experience shortness of breath, chest pain, coughing, and others.

According to the global asthma report published in 2018, it was estimated that there were 339.00 million patients worldwide who were affected with asthma disease in the year 2016.  The market growth is increased by growing asthmatic population, rising consumption of smoke, exposure to certain toxin or change in environment and introduction of novel therapies may increase the asthma disease drug market.

Market Drivers

  • Increase in prevalence rate of asthma Disease worldwide
  • Exposure to certain toxin or change in environment may increase the asthma disease
  • Chronic consumption of tobacco and smoke
  • Prevalence of indoor as well as outdoor allergens
  • Rising awareness about treatment and technological advancement is driving the growth of market
  • Increase in the rate of R&D initiatives is driving asthma disease drug market

Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
  • Lack of awareness about clinical development and novel therapies for asthma disease treatment

Speak To Industry Experts, Request For Details Report@

Segmentation: Global Asthma Disease Market

By Classification Type

  • Mild intermittent asthma
  • Mild persistent asthma
  • Moderate persistent asthma
  • Severe persistent asthma

By Duration of Action Type

  • Long-term asthma control medications
  • Inhaled corticosteroids
    • Beclomethasone dipropionate
    • Omalizumab
    • Fluticasone furoate inhalation powder
    • Prednisone delayed-release tablets
    • Mometasone furoate and formoterol fumarate dihydrate
  • Anticholinergics
  • Tiotropium bromide
  • Leukotriene modifiers
    • Reslizumab
    • Mepolizumab
    • Montelukast
  • Long-acting beta agonists
  • Salmeterol
  • Formoterol
  • Arformoterol
  • Theophylline
  • Quick-relief (rescue) medications
  • Short Acting Beta Agonists
  • Albuterol sulfate
  • Salbutamol
  • Others
    • Ipratropium
  • Allergy medications
  • Allergy shots (immunotherapy)
  • Omalizumab (Xolair)
  • Others

By Route of administration

  • Oral
  • Inhaled
  • Intravenous
  • Others

By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific
  • Middle East & Africa
    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In May 2019, Regeneron Pharmaceuticals, Inc. in a collaboration with Sanofi S.A. received approval from the European Commission for Dupixent (dupilumab) for the treatment of severe asthma with type 2 inflammation in adults and adolescents 12 years and older as an add-on maintenance treatment
  • In October 2018, Regeneron Pharmaceuticals, Inc. in collaboration with Sanofi S.A. received FDA approval for Dupixent (dupilumab) for the treatment of moderate-to-severe asthma patient of aged 12 years and older given in combination with an eosinophilic phenotype or with oral corticosteroid-dependent asthma
  • In February 2019, Mylan N.V received the Abbreviated New Drug Application (ANDA) approval from the FDA for the Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP) which is the first generic version of the GlaxoSmithKline’s Advair Diskus. This drug is used for the treatment of asthma or other chronic obstructive pulmonary disease (COPD)

Browse full TOC @

Competitive Analysis: Global Asthma Disease Market

Global asthma disease market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of asthma disease market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players: Global Asthma Disease Market

Few of the major competitors currently working in the global asthma disease market are, GlaxoSmithKline Plc (UK), Regeneron Pharmaceuticals (US), Mylan N.V (US), Sanofi S.A (France),  Teva Pharmaceutical Industries Ltd  (Israel), GlaxoSmithKline Plc (UK), F. Hoffmann-La Roche Ltd (Switzerland),  Pfizer Inc., Novartis AG, AstraZeneca, Abbott, Vectura Group plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH (Germany),  Sunovion Pharmaceuticals Inc. (US), Merck & Co., Inc. (US), Eli Lilly and Company, AbbVie Inc and few among others.

Make an Inquiry for Discount On this Report

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

Tel: +1-888-387-2818



Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *